Phase transformation considerations during process development and manufacture of solid oral dosage forms.
D000082:Acetaminophen / Q000737:chemistry; D000284:Administration, Oral; D001241:Aspirin / Q000737:chemistry; D002214:Capsules / Q000008:administration & dosage / Q000737:chemistry; D002220:Carbamazepine / Q000737:chemistry; D002623:Chemistry Techniques, Analytical; D003460:Crystallization; D004339:Drug Compounding; D004355:Drug Stability; D005079:Excipients / Q000008:administration & dosage / Q000737:chemistry; D005612:Freeze Drying; D006801:Humans; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000737:chemistry*; D044367:Phase Transition; D019438:Ritonavir / Q000737:chemistry; D012997:Solvents / Q000737:chemistry; D013607:Tablets / Q000008:administration & dosage / Q000737:chemistry; D013678:Technology, Pharmaceutical; D013806:Theophylline / Q000737:chemistry; D013816:Thermodynamics; D013831:Thiamine / Q000737:chemistry; D044366:Transition Temperature; D014867:Water / Q000737:chemistry
D002214:Capsules; D005079:Excipients; D004364:Pharmaceutical Preparations; D012997:Solvents; D013607:Tablets; D014867:Water; D002220:Carbamazepine; D000082:Acetaminophen; D013806:Theophylline; D019438:Ritonavir; D001241:Aspirin; D013831:Thiamine